Amphastar Pharmaceuticals, Inc. Operating Cash Flow
Amphastar Pharmaceuticals, Inc. (AMPH) reported Operating Cash Flow of $99.16 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- Amphastar Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $51.32M, a 44.20% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $47.84M, a 36.39% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $32.86M, a 13.23% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $52.58M, a 12.31% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2025 was $156.12M, a 26.84% decline from fiscal 2024.
- Amphastar Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2024 was $213.39M, a 16.28% increase from fiscal 2023.
- Amphastar Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2023 was $183.50M, a 105.76% increase from fiscal 2022.
- Amphastar Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2022 was $89.18M, a 8.99% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $51.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $99.16M 10-Q · filed 2026-08-06 | $132.03M derived: sum of 3 quarters · filed 2026-08-06 | $184.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $47.84M 10-Q · filed 2026-05-07 | $80.70M derived: sum of 2 quarters · filed 2026-05-07 | $133.29M derived: sum of 3 quarters · filed 2026-05-07 | $168.88M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $32.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $85.45M derived: sum of 2 quarters · filed 2026-02-26 | $121.04M derived: sum of 3 quarters · filed 2026-08-06 | $156.12M 10-K · filed 2026-02-26 |
| 2025-09-30 | $52.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $88.17M derived: sum of 2 quarters · filed 2026-08-06 | $123.25M 10-Q · filed 2025-11-06 | $152.28M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $35.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $70.67M 10-Q · filed 2026-08-06 | $99.69M derived: sum of 3 quarters · filed 2026-08-06 | $159.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $35.08M 10-Q · filed 2026-05-07 | $64.10M derived: sum of 2 quarters · filed 2026-05-07 | $124.06M derived: sum of 3 quarters · filed 2026-05-07 | $193.17M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $29.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $88.99M derived: sum of 2 quarters · filed 2026-02-26 | $158.09M derived: sum of 3 quarters · filed 2026-02-26 | $213.39M 10-K · filed 2026-02-26 |
| 2024-09-30 | $59.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $129.07M derived: sum of 2 quarters · filed 2025-11-06 | $184.36M 10-Q · filed 2025-11-06 | $208.23M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $69.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $124.40M 10-Q · filed 2025-08-07 | $148.26M derived: sum of 3 quarters · filed 2026-02-26 | $212.60M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $55.29M 10-Q · filed 2025-05-08 | $79.16M derived: sum of 2 quarters · filed 2026-02-26 | $143.49M derived: sum of 3 quarters · filed 2026-02-26 | $198.41M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $23.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $88.20M derived: sum of 2 quarters · filed 2026-02-26 | $143.12M derived: sum of 3 quarters · filed 2026-02-26 | $183.50M 10-K · filed 2026-02-26 |
| 2023-09-30 | $64.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $119.26M derived: sum of 2 quarters · filed 2024-11-07 | $159.64M 10-Q · filed 2024-11-07 | $174.87M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $54.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $95.31M 10-Q · filed 2024-08-09 | $110.53M derived: sum of 3 quarters · filed 2025-03-03 | $130.91M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $40.38M 10-Q · filed 2024-05-10 | $55.61M derived: sum of 2 quarters · filed 2025-03-03 | $75.98M derived: sum of 3 quarters · filed 2025-03-03 | $78.80M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $15.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $35.60M derived: sum of 2 quarters · filed 2025-03-03 | $38.42M derived: sum of 3 quarters · filed 2025-03-03 | $89.18M 10-K · filed 2025-03-03 |
| 2022-09-30 | $20.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $23.19M derived: sum of 2 quarters · filed 2023-11-08 | $73.95M 10-Q · filed 2023-11-08 | $114.40M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $2.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $53.58M 10-Q · filed 2023-08-09 | $94.02M derived: sum of 3 quarters · filed 2024-02-29 | $96.59M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $50.77M 10-Q · filed 2023-05-09 | $91.21M derived: sum of 2 quarters · filed 2024-02-29 | $93.78M derived: sum of 3 quarters · filed 2024-02-29 | $125.93M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $40.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $43.01M derived: sum of 2 quarters · filed 2024-02-29 | $75.17M derived: sum of 3 quarters · filed 2024-02-29 | $97.99M 10-K · filed 2024-02-29 |
| 2021-09-30 | $2.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $34.73M derived: sum of 2 quarters · filed 2022-11-08 | $57.55M 10-Q · filed 2022-11-08 | $74.45M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $32.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $54.98M 10-Q · filed 2022-08-09 | $71.88M derived: sum of 3 quarters · filed 2023-03-01 | $80.68M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $22.82M 10-Q · filed 2022-05-10 | $39.72M derived: sum of 2 quarters · filed 2023-03-01 | $48.52M derived: sum of 3 quarters · filed 2023-03-01 | $78.61M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $16.89M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $25.70M derived: sum of 2 quarters · filed 2023-03-01 | $55.79M derived: sum of 3 quarters · filed 2023-03-01 | $57.27M 10-K · filed 2023-03-01 |
| 2020-09-30 | $8.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $38.90M derived: sum of 2 quarters · filed 2021-11-09 | $40.37M 10-Q · filed 2021-11-09 | $46.02M derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-06-30 | $30.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $31.57M 10-Q · filed 2021-08-09 | $37.22M derived: sum of 3 quarters · filed 2022-03-11 | $25.21M derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-03-31 | $1.48M 10-Q · filed 2021-05-07 | $7.13M derived: sum of 2 quarters · filed 2022-03-11 | -$4.87M derived: sum of 3 quarters · filed 2022-03-11 | $46.85M derived: sum of 4 quarters · filed 2022-03-11 |
| 2019-12-31 | $5.65M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | -$6.35M derived: sum of 2 quarters · filed 2022-03-11 | $45.37M derived: sum of 3 quarters · filed 2022-03-11 | $41.76M 10-K · filed 2022-03-11 |
| 2019-09-30 | -$12.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $39.72M derived: sum of 2 quarters · filed 2020-11-06 | $36.11M 10-Q · filed 2020-11-06 | $45.63M derived: sum of 4 quarters · filed 2021-03-15 |
| 2019-06-30 | $51.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $48.11M 10-Q · filed 2020-08-07 | $57.63M derived: sum of 3 quarters · filed 2021-03-15 | $73.41M derived: sum of 4 quarters · filed 2021-03-15 |
| 2019-03-31 | -$3.61M 10-Q · filed 2020-05-11 | $5.91M derived: sum of 2 quarters · filed 2021-03-15 | $21.69M derived: sum of 3 quarters · filed 2021-03-15 | $26.22M derived: sum of 4 quarters · filed 2021-03-15 |
| 2018-12-31 | $9.52M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $25.30M derived: sum of 2 quarters · filed 2021-03-15 | $29.83M derived: sum of 3 quarters · filed 2021-03-15 | $38.19M 10-K · filed 2021-03-15 |
| 2018-09-30 | $15.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $20.31M derived: sum of 2 quarters · filed 2019-11-08 | $28.67M 10-Q · filed 2019-11-08 | $38.44M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-06-30 | $4.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $12.89M 10-Q · filed 2019-08-09 | $22.66M derived: sum of 3 quarters · filed 2020-03-16 | $25.13M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-03-31 | $8.36M 10-Q · filed 2019-05-10 | $18.13M derived: sum of 2 quarters · filed 2020-03-16 | $20.60M derived: sum of 3 quarters · filed 2020-03-16 | $25.17M derived: sum of 4 quarters · filed 2020-03-16 |
| 2017-12-31 | $9.77M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $12.24M derived: sum of 2 quarters · filed 2020-03-16 | $16.81M derived: sum of 3 quarters · filed 2020-03-16 | $39.21M 10-K · filed 2020-03-16 |
| 2017-09-30 | $2.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $7.05M derived: sum of 2 quarters · filed 2018-11-09 | $29.44M 10-Q · filed 2018-11-09 | $43.45M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-06-30 | $4.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $26.97M 10-Q · filed 2018-08-09 | $40.98M derived: sum of 3 quarters · filed 2019-03-15 | |
| 2017-03-31 | $22.40M 10-Q · filed 2018-05-10 | $36.40M derived: sum of 2 quarters · filed 2019-03-15 | ||
| 2016-12-31 | $14.01M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $38.56M 10-K · filed 2019-03-15 | ||
| 2016-09-30 | $24.55M 10-Q · filed 2017-11-09 | |||
| 2015-12-31 | $10.68M 10-K · filed 2018-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |